Info: Read More
  • 中药标准品生产商,产品定制服务
  • 人参皂苷Rg1

    Ginsenoside Rg1

    产品编号 CFN99967
    CAS编号 22427-39-0
    分子式 = 分子量 C42H72O14 = 801.01
    产品纯度 >=98%
    物理属性 White powder
    化合物类型 Triterpenoids
    植物来源 The roots of Panax ginseng C. A. Mey.
    产品名称 产品编号 CAS编号 包装 QQ客服
    人参皂苷Rg1 CFN99967 22427-39-0 10mg QQ客服:3257982914
    人参皂苷Rg1 CFN99967 22427-39-0 20mg QQ客服:3257982914
    人参皂苷Rg1 CFN99967 22427-39-0 50mg QQ客服:3257982914
    人参皂苷Rg1 CFN99967 22427-39-0 100mg QQ客服:3257982914
    1. 在您收到产品后请检查产品。如无问题,请将产品存入冰霜并且样品瓶保持密封,产品可以存放长达24个月(2-8摄氏度)。

    2. 只要有可能,产品溶解后,您应该在同一天应用于您的实验。 但是,如果您需要提前做预实验,或者需要全部溶解,我们建议您将溶液以等分试样的形式存放在-20℃的密封小瓶中。 通常,这些可用于长达两周。 使用前,打开样品瓶前,我们建议您将产品平衡至室温至少1小时。

    3. 需要更多关于溶解度,使用和处理的建议? 请发送电子邮件至
  • 1. 在线订购
  • 请联系我们QQ客服

  • 2. 电话订购
  • 请拨打电话:
    027-84237683 或 027-84237783

  • 3. 邮件或传真订购
  • 发送电子邮件到: 或

  • 提供订购信息
  • 为了方便客户的订购,请需要订购ChemFaces产品的客户,在下单的时候请提供下列信息,以供我们快速为您建立发货信息。
  • 1. 产品编号(CAS No.或产品名称)
  • 2. 发货地址
  • 3. 联系方法 (联系人,电话)
  • 4. 开票抬头 (如果需要发票的客户)
  • 5. 发票地址(发货地址与发票地址不同)
  • 发货时间
    1. 付款方式为100%预付款客户,我们将在确认收到货款后当天或1-3个工作日发货。

    2. 付款方式为月结的客户,我们承诺在收到订单后当天或1-3个工作日内发货。

    3. 如果客户所需要的产品,需要重新生产,我们有权告知客户,交货时间需要延期。

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.

    PMID: 29328914

    Cell Metab. 2020 Mar 3;31(3):534-548.e5.
    doi: 10.1016/j.cmet.2020.01.002.

    PMID: 32004475

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.

    PMID: 29149595

    ACS Nano. 2018 Apr 24;12(4): 3385-3396.
    doi: 10.1021/acsnano.7b08969.

    PMID: 29553709

    Nature Plants. 2016 Dec 22;3: 16206.
    doi: 10.1038/nplants.2016.205.

    PMID: 28005066

    Sci Adv. 2018 Oct 24;4(10): eaat6994.
    doi: 10.1126/sciadv.aat6994.

    PMID: 30417089
  • Center for protein Engineering (CIP) (Belgium)
  • University of Vigo (Spain)
  • Calcutta University (India)
  • University of Cincinnati (USA)
  • Leibniz-Institut für Pflanzenbiochemie (IPB) (Germany)
  • Florida A&M University (USA)
  • Aarhus University (Denmark)
  • Vin?a Institute of Nuclear Sciences (Serbia)
  • National Cancer Center Research Institute (Japan)
  • S.N.D.T. Women's University (India)
  • University of Amsterdam (Netherlands)
  • Universiti Malaysia Pahang (Malaysia)
  • University of Minnesota (USA)
  • Warszawski Uniwersytet Medyczny (Poland)
  • More...
  • 国外学术期刊发表的引用ChemFaces产品的部分文献
  • J Cosmet Dermatol.2022, 21(1):396-402.
  • Oxid Med Cell Longev.2022, 2022:9139338.
  • Journal of Food Composition and Analysis2021, 100:103905.
  • Evid Based Complement Alternat Med.2017, 2017:1401279
  • Adaptive Medicine 2020, 12(1): 4-10
  • J Agric Food Chem.2021, 69(14):4210-4222.
  • Org Biomol Chem.2017, 15(31):6483-6492
  • Cancers (Basel).2021, 13(9):2223.
  • Chung Shan Medical University2020, US20200323790A1
  • African J. Agricultural Research 2017, 12(13):1164-1168
  • LWT2020, 124:109163
  • J of Engineering Science&Technology2018, 13(9):2820-2828
  • Appl. Sci.2020, 10(23), 8729
  • Br J Pharmacol.2020, 10.1111
  • PLoS One.2021, 16(9):e0257243.
  • Oncol Rep.2019, 41(4):2453-2463
  • Tumour Biol.2015, 36(9):7027-34
  • Int J Anal Chem.2017, 2017:1254721
  • Pharmaceutics.2021, 13(2):187.
  • Int J Mol Sci.2019, 20(11):E2734
  • Chem Biol Interact.2019, 298:1-7
  • Front Pharmacol.2022, 13:806869.
  • Food Chem.2020, 313:126079
  • ...
  • 生物活性
    Description: Ginsenoside Rg1 has antiaging, anti-platelet activation, promotion of wound healing, and neuroprotective effects, it has protective effect against Aβ25-35-induced toxicity in PC12 cells,might be through the insulin-like growth factor-I receptor (IGF-IR) and estrogen receptor (ER)signaling pathways. Ginsenoside Rg1 is a desirable agent for enhancing CD4+ T-cell activity, as well as the correction of Th1-dominant pathological disorders, which by increasing Th2 specific cytokine secretion and by repressing Th1 specific cytokine production. It increased the expression of the vascular endothelial growth factor (VEGF) mRNA and reduced ERK pathway, expression of transforming growth factor beta (TGF-β) mRNA.
    Targets: ERK | Akt | MEK | PI3K | Bcl-2/Bax | Beta Amyloid | VEGFR | TGF-β/Smad | IFN-γ | IL Receptor | gp120/CD4 | IGF-IR | Estrogen receptor
    In vitro:
    Acta Pharmacol Sin. 2009 Mar;30(3):299-306.
    Ginsenoside Rg1 promotes endothelial progenitor cell migration and proliferation.[Pubmed: 19262553]
    To investigate the effect of Ginsenoside Rg1 on the migration, adhesion, proliferation, and VEGF expression of endothelial progenitor cells (EPCs).
    EPCs were isolated from human peripheral blood and incubated with different concentrations of Ginsenoside Rg1 (0.1, 0.5, 1.0, and 5.0 micromol/L) and vehicle controls. EPC migration was detected with a modified Boyden chamber assay. EPC adhesion was determined by counting adherent cells on fibronectin-coated culture dishes. EPC proliferation was analyzed with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. In vitro vasculogenesis was assayed using an in vitro vasculogenesis detection kit. A VEGF-ELISA kit was used to measure the amount of VEGF protein in the cell culture medium. Ginsenoside Rg1 promoted EPC adhesion, proliferation, migration and in vitro vasculogenesis in a dose- and time-dependent manner. Cell cycle analysis showed that 5.0 micromol/L of Ginsenoside Rg1 significantly increased the EPC proliferative phase (S phase) and decreased the resting phase (G(0)/G(1) phase). Ginsenoside Rg1 increased vascular endothelial growth factor production.
    The results indicate that Ginsenoside Rg1 promotes proliferation, migration, adhesion and in vitro.
    Int Immunopharmacol. 2004 Feb;4(2):235-44.
    Ginsenoside Rg1 enhances CD4(+) T-cell activities and modulates Th1/Th2 differentiation.[Pubmed: 14996415]
    Panax ginseng is commonly used as a tonic medicine in Asian countries such as Korea, China, and Japan. It has been reported that Ginsenoside Rg1 in P. ginseng increases the proportion of T helper (Th) cells among the total number of T cells and promotes IL-2 gene expression in murine splenocytes. This implies that Ginsenoside Rg1 increases the immune activity of CD4(+) T cells, however, the exact mechanism remains unknown.
    The present study elucidated the direct effect of Rg1 on helper T-cell activities and on Th1/Th2 lineage development. The results demonstrated that Ginsenoside Rg1 had no mitogenic effects on unstimulated CD4(+) T cells, but augmented CD4(+) T-cell proliferation upon activation with anti-CD3/anti-CD28 antibodies in a dose-dependent manner. Rg1 also enhanced the expression of cell surface protein CD69 on CD4(+) T cells. In Th0 condition, Ginsenoside Rg1 increases the expression of IL-2 mRNA, and enhances the expression of IL-4 mRNA on CD4(+) T cells, suggesting that Rg1 prefers to induce Th2 lineage development. In addition, Ginsenoside Rg1 increases IL-4 secretion in CD4(+) T cells under Th2 skewed condition, while decreasing IFN-gamma secretion of cells in Th1 polarizing condition. Thus, Rg1 enhances Th2 lineage development from the naïve CD4(+) T cell both by increasing Th2 specific cytokine secretion and by repressing Th1 specific cytokine production.
    Therefore, these results suggest that Ginsenoside Rg1 is a desirable agent for enhancing CD4(+) T-cell activity, as well as the correction of Th1-dominant pathological disorders.
    Oncotarget . 2017 Jul 24;8(33):55384-55393.
    Ginsenoside Rg1 attenuates adjuvant-induced arthritis in rats via modulation of PPAR-γ/NF-κB signal pathway[Pubmed: 28903427]
    Ginsenoside Rg1, the main active compound in Panax ginseng, has already been shown to have anti-inflammatory effects. However, the protective effects of Rg1 on rheumatoid arthritis (RA) remain unclear. The aim of the present study was to investigate the effects and mechanisms of Rg1 on adjuvant-induced arthritis (AIA) in rats. AIA rats were given Rg1 at doses of 5, 10, and 20 mg/kg intraperitoneally for 14 days to observe the anti-arthritic effects. The results showed that Rg1 significantly alleviated joint swelling and injuries. Rg1 can also significantly reduce the level of TNF-α and IL-6, increase PPAR-γ protein expression, inhibit IκBα phosphorylation and NF-κB nuclear translocation in the inflammatory joints of AIA rats and RAW264.7 cells stimulated by lipopolysaccharide (LPS). The results indicate that Rg1 has therapeutic effects on AIA rats, and the mechanism might be associated with its anti-inflammatory effects by up-regulating PPAR-γ and subsequent inhibition of NF-κB signal pathway.
    J Ginseng Res . 2016 Jan;40(1):9-17.
    A UPLC/MS-based metabolomics investigation of the protective effect of ginsenosides Rg1 and Rg2 in mice with Alzheimer's disease[Pubmed: 26843817]
    Background: Alzheimer's disease (AD) is a progressive brain disease, for which there is no effective drug therapy at present. Ginsenoside Rg1 (G-Rg1) and G-Rg2 have been reported to alleviate memory deterioration. However, the mechanism of their anti-AD effect has not yet been clearly elucidated. Methods: Ultra performance liquid chromatography tandem MS (UPLC/MS)-based metabolomics was used to identify metabolites that are differentially expressed in the brains of AD mice with or without ginsenoside treatment. The cognitive function of mice and pathological changes in the brain were also assessed using the Morris water maze (MWM) and immunohistochemistry, respectively. Results: The impaired cognitive function and increased hippocampal Aβ deposition in AD mice were ameliorated by G-Rg1 and G-Rg2. In addition, a total of 11 potential biomarkers that are associated with the metabolism of lysophosphatidylcholines (LPCs), hypoxanthine, and sphingolipids were identified in the brains of AD mice and their levels were partly restored after treatment with G-Rg1 and G-Rg2. G-Rg1 and G-Rg2 treatment influenced the levels of hypoxanthine, dihydrosphingosine, hexadecasphinganine, LPC C 16:0, and LPC C 18:0 in AD mice. Additionally, G-Rg1 treatment also influenced the levels of phytosphingosine, LPC C 13:0, LPC C 15:0, LPC C 18:1, and LPC C 18:3 in AD mice. Conclusion: These results indicate that the improvements in cognitive function and morphological changes produced by G-Rg1 and G-Rg2 treatment are caused by regulation of related brain metabolic pathways. This will extend our understanding of the mechanisms involved in the effects of G-Rg1 and G-Rg2 on AD.
    In vivo:
    J Gerontol A Biol Sci Med Sci. 2014 Mar;69(3):282-94.
    Long-term ginsenoside Rg1 supplementation improves age-related cognitive decline by promoting synaptic plasticity associated protein expression in C57BL/6J mice.[Pubmed: 23833204 ]
    In aging individuals, age-related cognitive decline is the most common cause of memory impairment. Among the remedies, ginsenoside Rg1, a major active component of ginseng, is often recommended for its antiaging effects. However, its role in improving cognitive decline during normal aging remains unknown and its molecular mechanism partially understood.
    This study employed a scheme of Rg1 supplementation for female C57BL/6J mice, which started at the age of 12 months and ended at 24 months, to investigate the effects of Rg1 supplementation on the cognitive performance. We found that Rg1 supplementation improved the performance of aged mice in behavior test and significantly upregulated the expression of synaptic plasticity-associated proteins in hippocampus, including synaptophysin, N-methyl-D-aspartate receptor subunit 1, postsynaptic density-95, and calcium/calmodulin-dependent protein kinase II alpha, via promoting mammalian target of rapamycin pathway activation.
    These data provide further support for Rg1 treatment of cognitive degeneration during aging.
    Thromb Res. 2014 Jan;133(1):57-65.
    Ginsenoside Rg1 inhibits platelet activation and arterial thrombosis.[Pubmed: 24196231 ]
    Derived from the root of Panax ginseng C.A.Mey, Panax notoginsenosides (PNS) is a widely used herbal medicine to treat atherothrombotic diseases in Asian medicine. Ginsenoside Rg1 is one of the main compounds responsible for the pharmaceutical actions of PNS. As platelets play pivotal roles in atherothrombogenesis, we therefore studied the effect of Rg1 on platelet activation and its underlying mechanisms.
    Human platelets are obtained from healthy subjects. Platelet activation and the inhibition of Rg1 were assessed by Born aggregometer, flow cytmetry, flow chamber and western blot. The in vivo thrombosis model was induced by 10% FeCl3 on mesenteric arterioles of wild type B57/b6 mice. Rg1 significantly inhibited platelet aggregation induced by thrombin, ADP, collagen and U46619, e.g., aggregation rate stimulated by 0.1UmL(-1) thrombin was decreased 46% by Rg1. Rg1 also reduced thrombin (0.1UmL(-1))-enhanced fibrinogen binding and P-selectin expression of single platelet by 81% and 66%, respectively. Rg1 affected αIIbβ3-mediated outside-in signaling as demonstrated by diminished platelet spreading on immobilized fibrinogen. Rg1 also decreased the rate of clot retraction in platelet rich plasma. Furthermore, Rg1 decreased platelet adhesion on collagen surface under a shear rate correlated to the arterial flow (1000s(-1)) by approximately 70%. Western blot showed that Rg1 potently inhibited ERK phosphrylation. The in vitro findings were further evaluated in the mouse model of in vivo arterial thrombosis, and Rg1 was found to prolong the mesenteric arterial occlusion time (34.9±4.1min without and 64.3±4.9min with Rg1; p<0.01).
    Rg1 inhibits platelet activation via the inhibition of ERK pathway, and attenuates arterial thrombus formation in vivo.
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 1.2484 mL 6.2421 mL 12.4842 mL 24.9685 mL 31.2106 mL
    5 mM 0.2497 mL 1.2484 mL 2.4968 mL 4.9937 mL 6.2421 mL
    10 mM 0.1248 mL 0.6242 mL 1.2484 mL 2.4968 mL 3.1211 mL
    50 mM 0.025 mL 0.1248 mL 0.2497 mL 0.4994 mL 0.6242 mL
    100 mM 0.0125 mL 0.0624 mL 0.1248 mL 0.2497 mL 0.3121 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    产品名称 产品编号 CAS编号 分子式 = 分子量 位单 联系QQ
    三七皂苷Fa; Notoginsenoside Fa CFN93284 88100-04-3 C59H100O27 = 1241.4 20mg QQ客服:3257982914
    三七皂苷R4; Notoginsenoside R4 CFN91142 87741-77-3 C59H100O27 = 1241.4 5mg QQ客服:3257982914
    人参皂苷Ra2; Ginsenoside Ra2 CFN93293 83459-42-1 C58H98O26 = 1211.39 5mg QQ客服:1413575084
    三七皂苷Fe; Notoginsenoside Fe CFN93282 88105-29-7 C47H80O17 = 917.12 20mg QQ客服:2056216494
    人参皂苷Rc; Ginsenoside Rc CFN99973 11021-14-0 C53H90O22 = 1079.27 20mg QQ客服:215959384
    人参皂苷F1; Ginsenoside F1 CFN99754 53963-43-2 C36H62O9 = 638.88 20mg QQ客服:2056216494
    3-乙酰人参皂苷F1; 3-Acetyl-ginsenoside F1 CFN95238 1881225-08-6 C38H64O10 = 680.9 5mg QQ客服:1457312923
    人参皂苷F3; Ginsenoside F3 CFN99978 62025-50-7 C41H70O13 = 770.99 10mg QQ客服:2159513211
    人参皂苷F5; Ginsenoside F5 CFN95034 189513-26-6 C41H70O13 = 771.0 20mg QQ客服:2056216494
    人参皂苷Rg1; Ginsenoside Rg1 CFN99967 22427-39-0 C42H72O14 = 801.01 20mg QQ客服:2056216494





    在线QQ: 1413575084


    ChemFaces为科学家,科研人员与企业提供快速的产品递送。我们通过瑞士SGS ISO 9001:2008质量体系认证天然化合物与对照品的研发和生产